JP2007505149A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007505149A5 JP2007505149A5 JP2006526389A JP2006526389A JP2007505149A5 JP 2007505149 A5 JP2007505149 A5 JP 2007505149A5 JP 2006526389 A JP2006526389 A JP 2006526389A JP 2006526389 A JP2006526389 A JP 2006526389A JP 2007505149 A5 JP2007505149 A5 JP 2007505149A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- cycloalkyl
- cycloheteroalkyl
- prodrug
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 36
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 36
- 125000001072 heteroaryl group Chemical group 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 28
- 239000000651 prodrug Substances 0.000 claims description 28
- 229940002612 prodrug Drugs 0.000 claims description 28
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 27
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 22
- 125000003118 aryl group Chemical group 0.000 claims description 21
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 21
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 21
- 125000002252 acyl group Chemical group 0.000 claims description 18
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 18
- 125000003107 substituted aryl group Chemical group 0.000 claims description 18
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical class NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 14
- 206010046543 Urinary incontinence Diseases 0.000 claims description 12
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 12
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000012453 solvate Substances 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- -1 4- Imidazolylmethyl Chemical group 0.000 claims 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229960002870 gabapentin Drugs 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000009245 menopause Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229960001233 pregabalin Drugs 0.000 claims 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 208000022170 stress incontinence Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 230000009747 swallowing Effects 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000001960 triggered effect Effects 0.000 claims 1
- 206010046494 urge incontinence Diseases 0.000 claims 1
- 0 COC(CC1(C*)CCCCC1)=* Chemical compound COC(CC1(C*)CCCCC1)=* 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50258503P | 2003-09-11 | 2003-09-11 | |
| US50521003P | 2003-09-22 | 2003-09-22 | |
| US51228803P | 2003-10-17 | 2003-10-17 | |
| US53874804P | 2004-01-22 | 2004-01-22 | |
| PCT/US2004/029944 WO2005025562A1 (en) | 2003-09-11 | 2004-09-13 | Treating and/or preventing urinary incontinence using prodrugs of gaba analogs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007505149A JP2007505149A (ja) | 2007-03-08 |
| JP2007505149A5 true JP2007505149A5 (enExample) | 2007-09-13 |
Family
ID=34317683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006526389A Pending JP2007505149A (ja) | 2003-09-11 | 2004-09-13 | ギャバ類似体のプロドラッグを用いる尿失禁の治療および／あるいは予防 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7700652B2 (enExample) |
| EP (1) | EP1670451A4 (enExample) |
| JP (1) | JP2007505149A (enExample) |
| KR (1) | KR20060119971A (enExample) |
| AU (1) | AU2004272111A1 (enExample) |
| CA (1) | CA2537837A1 (enExample) |
| IL (1) | IL174409A0 (enExample) |
| MX (1) | MXPA06002731A (enExample) |
| NO (1) | NO20061625L (enExample) |
| NZ (1) | NZ545884A (enExample) |
| WO (1) | WO2005025562A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7186855B2 (en) * | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
| UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| US7025745B2 (en) * | 2002-10-07 | 2006-04-11 | Advanced Cardiovascular Systems, Inc. | Method of making a catheter balloon using a tapered mandrel |
| JP2007505149A (ja) | 2003-09-11 | 2007-03-08 | ゼノポート，インコーポレイティド | ギャバ類似体のプロドラッグを用いる尿失禁の治療および／あるいは予防 |
| SI1677767T1 (sl) * | 2003-10-14 | 2011-11-30 | Xenoport Inc | Kristalinična oblika analoga gama-aminomaslene kisline |
| CN101068538A (zh) | 2004-11-04 | 2007-11-07 | 什诺波特有限公司 | 加巴喷丁前体药物持续释放口服剂型 |
| ES2646326T3 (es) | 2005-08-03 | 2017-12-13 | Sprout Pharmaceuticals, Inc. | Uso de flibanserina en el tratamiento de la obesidad |
| EP1928450A2 (en) * | 2005-08-26 | 2008-06-11 | Xenoport, Inc. | Treating premature ejaculation using gabapentin and pregabalin prodrugs |
| NL2000281C2 (nl) * | 2005-11-02 | 2007-08-07 | Pfizer Prod Inc | Vaste farmaceutische samenstellingen die pregabaline bevatten. |
| US20090312242A1 (en) | 2006-06-30 | 2009-12-17 | Ramiro Castro | Flibanserin for the treatment of urinary incontinence and related diseases |
| CA2672044A1 (en) * | 2006-12-08 | 2008-06-19 | Xenoport, Inc. | Use of prodrugs of gaba analogs for treating diseases |
| HRP20110634T1 (hr) | 2006-12-22 | 2011-10-31 | Recordati Ireland Limited | KOMBINIRANA TERAPIJA LIGANADA α<SUB>2</SUB>δ I NSAID ZA POREMEĆAJE DONJEG URINARNOG TRAKTA |
| TWI369982B (en) * | 2007-01-11 | 2012-08-11 | Xenoport Inc | Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment |
| UY31335A1 (es) | 2007-09-12 | 2009-04-30 | Tratamiento de sintomas vasomotores | |
| WO2009087682A2 (en) * | 2007-12-28 | 2009-07-16 | Intas Pharmaceuticals Limited | Stabilized injectable formulation of pregabalin |
| JP5291123B2 (ja) * | 2008-01-25 | 2013-09-18 | ゼノポート，インコーポレイティド | （３ｓ）−アミノメチル−５−ヘキサン酸プロドラッグの結晶形態及びその使用 |
| US7868043B2 (en) | 2008-01-25 | 2011-01-11 | Xenoport, Inc. | Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use |
| US7872046B2 (en) * | 2008-01-25 | 2011-01-18 | Xenoport, Inc. | Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use |
| CA2686480A1 (en) | 2008-12-15 | 2010-06-15 | Boehringer Ingelheim International Gmbh | New salts |
| NZ594648A (en) * | 2009-03-03 | 2013-12-20 | Xenoport Inc | Sustained release oral dosage forms of an r-baclofen prodrug |
| US8377956B2 (en) | 2010-03-01 | 2013-02-19 | Xenoport, Inc. | Use of (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl) butanoic acid for treating urinary incontinence |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2996431A (en) | 1953-12-16 | 1961-08-15 | Barry Richard Henry | Friable tablet and process for manufacturing same |
| US3402240A (en) | 1957-06-25 | 1968-09-17 | Pfizer & Co C | Medicinal tablet and process of making same |
| US3139383A (en) | 1961-06-26 | 1964-06-30 | Norton Co | Encapsulated time release pellets and method for encapsulating the same |
| US3962414A (en) | 1972-04-27 | 1976-06-08 | Alza Corporation | Structured bioerodible drug delivery device |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3811444A (en) | 1972-12-27 | 1974-05-21 | Alza Corp | Bioerodible ocular device |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| DE2336218C3 (de) | 1973-07-17 | 1985-11-14 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Orale Arzneiform |
| US3992518A (en) | 1974-10-24 | 1976-11-16 | G. D. Searle & Co. | Method for making a microsealed delivery device |
| GB1478759A (en) | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
| DE2460891C2 (de) | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US4093709A (en) | 1975-01-28 | 1978-06-06 | Alza Corporation | Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates) |
| US4063064A (en) | 1976-02-23 | 1977-12-13 | Coherent Radiation | Apparatus for tracking moving workpiece by a laser beam |
| US4079038A (en) | 1976-03-05 | 1978-03-14 | Alza Corporation | Poly(carbonates) |
| US4066747A (en) | 1976-04-08 | 1978-01-03 | Alza Corporation | Polymeric orthoesters housing beneficial drug for controlled release therefrom |
| US4070347A (en) | 1976-08-16 | 1978-01-24 | Alza Corporation | Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality |
| US4200098A (en) | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
| US4285987A (en) | 1978-10-23 | 1981-08-25 | Alza Corporation | Process for manufacturing device with dispersion zone |
| US4434153A (en) | 1982-03-22 | 1984-02-28 | Alza Corporation | Drug delivery system comprising a reservoir containing a plurality of tiny pills |
| US4421736A (en) | 1982-05-20 | 1983-12-20 | Merrel Dow Pharmaceuticals Inc. | Sustained release diethylpropion compositions |
| US4721613A (en) | 1982-12-13 | 1988-01-26 | Alza Corporation | Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use |
| US4820523A (en) | 1986-04-15 | 1989-04-11 | Warner-Lambert Company | Pharmaceutical composition |
| US4752470A (en) | 1986-11-24 | 1988-06-21 | Mehta Atul M | Controlled release indomethacin |
| US4816263A (en) | 1987-10-02 | 1989-03-28 | Alza Corporation | Dosage form for treating cardiovascular diseases comprising isradipine |
| US4853229A (en) | 1987-10-26 | 1989-08-01 | Alza Corporation | Method for adminstering tiny pills |
| DE3928183A1 (de) | 1989-08-25 | 1991-02-28 | Goedecke Ag | Lactamfreie cyclische aminosaeuren |
| US5827819A (en) | 1990-11-01 | 1998-10-27 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
| AU9137091A (en) | 1990-11-27 | 1992-06-25 | Northwestern University | Gaba and l-glutamic acid analogs for antiseizure treatment |
| US6197819B1 (en) | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| PT641330E (pt) | 1992-05-20 | 2002-03-28 | Univ Northwestern | Analogos de gaba e de acido l-glutamico para o tratamento de doencas do sistema nervoso central |
| US6287598B1 (en) | 1993-05-28 | 2001-09-11 | Alza Corporation | Method for providing sustained antiepileptic therapy |
| DK0888325T3 (da) | 1996-02-07 | 2002-09-16 | Warner Lambert Co | Cykliske aminosyrer som farmaceutiske midler |
| DE69709070T2 (de) | 1996-03-14 | 2002-06-20 | Warner-Lambert Co., Morris Plains | Verbrückte zyklische aminosäuren als pharmazeutische mittel |
| EA002765B1 (ru) | 1996-03-14 | 2002-08-29 | Варнер-Ламберт Компани | Производные циклической аминокислоты, фармацевтическая композиция на их основе и способ лечения эпилепсии, приступов слабости, гипокинезии, черепных нарушений, нейродегенеративных или невропатологических нарушений, депрессий, состояний тревоги и паники и боли |
| US6375987B1 (en) | 1996-10-01 | 2002-04-23 | Gattefossé, S.A. | Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix |
| CA2263663C (en) | 1996-10-23 | 2006-05-30 | Justin Stephen Bryans | Substituted gamma aminobutyric acids as pharmaceutical agents |
| AU8668598A (en) | 1997-08-20 | 1999-03-08 | University Of Oklahoma, The | Gaba analogs to prevent and treat gastrointestinal damage |
| DE69834204T2 (de) | 1997-10-27 | 2007-03-29 | Warner-Lambert Co. Llc | Zyklische aminosäuren und deren derivate als arzneimittel |
| PL341231A1 (en) | 1997-12-16 | 2001-03-26 | Warner Lambert Co | 4(3)-substitute derivatives of 4(3)aminomethyl(thio)pyrane or piperidine derivatives (analogues of garbapentin), their production and application in treating neurological disorders |
| ES2227896T3 (es) | 1997-12-16 | 2005-04-01 | Warner-Lambert Company Llc | Derivados de 1-aminometil-cicloalcanos sustituidos en 1 (=analogos de gabapentina), su preparacion y su uso en el tratamiento de trastornos neurologicos. |
| NZ503981A (en) | 1997-12-16 | 2002-12-20 | Warner Lambert Co | Novel amines, pharmaceutical compositions containing these amines, and uses thereof |
| WO1999061424A1 (en) | 1998-05-26 | 1999-12-02 | Warner-Lambert Company | Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel |
| FR2779651B1 (fr) | 1998-06-16 | 2001-04-20 | Gattefosse Ets Sa | Procede pour la fabrication de comprimes a liberation prolongee de principe(s) actif(s) presentant une cinetique de dissolution d'ordre zero |
| US6171615B1 (en) | 1998-07-06 | 2001-01-09 | Gattefoss{acute over (e)} | Sustained release theophylline formulations, excipient systems and methods of production |
| AU5478799A (en) | 1998-09-14 | 2000-04-03 | Warner-Lambert Company | Branched alkyl pyrrolidine-3-carboxylic acids |
| WO2000031020A1 (en) | 1998-11-25 | 2000-06-02 | Warner-Lambert Company | Improved gamma amino butyric acid analogs |
| EP1031350A1 (en) | 1999-02-23 | 2000-08-30 | Warner-Lambert Company | Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain |
| ES2313880T3 (es) * | 1999-04-08 | 2009-03-16 | Warner-Lambert Company Llc | Procedimiento para el tratamiento de la icontinencia. |
| US6992109B1 (en) * | 1999-04-08 | 2006-01-31 | Segal Catherine A | Method for the treatment of incontinence |
| CA2378918C (en) | 1999-07-22 | 2007-01-23 | University Of Rochester | Method of treating symptoms of hormonal variation, including hot flashes |
| US6793934B1 (en) | 1999-12-08 | 2004-09-21 | Shire Laboratories, Inc. | Solid oral dosage form |
| GB2362646A (en) | 2000-05-26 | 2001-11-28 | Warner Lambert Co | Cyclic amino acid derivatives useful as pharmaceutical agents |
| EP1296671B1 (en) | 2000-06-26 | 2008-03-26 | Warner-Lambert Company LLC | Gabapentin analogues for sleep disorders |
| GB2365425A (en) | 2000-08-01 | 2002-02-20 | Parke Davis & Co Ltd | Alkyl amino acid derivatives useful as pharmaceutical agents |
| WO2002028881A1 (en) | 2000-10-06 | 2002-04-11 | Xenoport, Inc. | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration |
| AU2002243204A1 (en) | 2000-10-06 | 2002-06-11 | Xenoport, Inc. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
| WO2002032376A2 (en) | 2000-10-06 | 2002-04-25 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
| US6683112B2 (en) | 2000-10-24 | 2004-01-27 | Andrx Corporation | Gabapentin prodrugs and formulations |
| GB2368579A (en) | 2000-10-31 | 2002-05-08 | Parke Davis & Co Ltd | Azole pharmaceutical agents |
| WO2002042414A2 (en) | 2000-11-17 | 2002-05-30 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7232924B2 (en) | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
| ATE540678T1 (de) * | 2001-06-11 | 2012-01-15 | Xenoport Inc | Prodrugs aus gaba-analoga, zusammensetzungen und ihre verwendungen |
| WO2002100349A2 (en) | 2001-06-13 | 2002-12-19 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of the parathroid hormone-2 (pth2) receptor to screen for agents to treat pain |
| EP1438290B1 (en) | 2001-08-09 | 2005-12-14 | Eli Lilly And Company | Cyclohept b!indole derivatives as spla2 inhibitors |
| AU2002316231A1 (en) | 2002-02-19 | 2003-09-29 | Xenoport, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
| AU2003243180A1 (en) * | 2002-05-17 | 2003-12-12 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| WO2004052360A1 (en) * | 2002-12-11 | 2004-06-24 | Xenoport, Inc. | Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof |
| WO2004053192A1 (en) * | 2002-12-11 | 2004-06-24 | Xenoport, Inc. | Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity |
| WO2004058168A2 (en) | 2002-12-20 | 2004-07-15 | Dynogen Pharmaceuticals, Inc. | METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS |
| CA2519694A1 (en) | 2003-03-21 | 2004-10-07 | Dynogen Pharmaceuticals, Inc. | Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators |
| JP2006522146A (ja) | 2003-03-31 | 2006-09-28 | ゼノポート，インコーポレイティド | Ｇａｂａ類似体のプロドラッグを使用するのぼせの治療または予防 |
| US7662987B2 (en) | 2003-07-15 | 2010-02-16 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl compounds |
| AU2004267100B2 (en) | 2003-08-20 | 2010-10-07 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use |
| JP2007505149A (ja) | 2003-09-11 | 2007-03-08 | ゼノポート，インコーポレイティド | ギャバ類似体のプロドラッグを用いる尿失禁の治療および／あるいは予防 |
| WO2005027850A2 (en) | 2003-09-17 | 2005-03-31 | Xenoport, Inc. | Treating or preventing restless legs syndrome using prodrugs of gaba analogs |
| SI1677767T1 (sl) | 2003-10-14 | 2011-11-30 | Xenoport Inc | Kristalinična oblika analoga gama-aminomaslene kisline |
| EP1716115B1 (en) | 2003-12-30 | 2013-02-27 | XenoPort, Inc. | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof |
| CN101068538A (zh) | 2004-11-04 | 2007-11-07 | 什诺波特有限公司 | 加巴喷丁前体药物持续释放口服剂型 |
| US20060222700A1 (en) | 2005-04-05 | 2006-10-05 | Groenewoud Pieter J | Tablet and capsule form of liquid active ingredient |
| AU2006325658B2 (en) | 2005-12-16 | 2010-04-08 | Hanmi Science Co., Ltd. | Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same |
| CA2669246A1 (en) | 2006-11-14 | 2008-05-22 | Xenoport, Inc. | Use of gabapentin and pregabalin prodrugs for treating tinnitus |
| CA2672044A1 (en) | 2006-12-08 | 2008-06-19 | Xenoport, Inc. | Use of prodrugs of gaba analogs for treating diseases |
| TWI369982B (en) | 2007-01-11 | 2012-08-11 | Xenoport Inc | Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment |
-
2004
- 2004-09-13 JP JP2006526389A patent/JP2007505149A/ja active Pending
- 2004-09-13 AU AU2004272111A patent/AU2004272111A1/en not_active Abandoned
- 2004-09-13 WO PCT/US2004/029944 patent/WO2005025562A1/en not_active Ceased
- 2004-09-13 MX MXPA06002731A patent/MXPA06002731A/es not_active Application Discontinuation
- 2004-09-13 KR KR1020067005033A patent/KR20060119971A/ko not_active Withdrawn
- 2004-09-13 CA CA002537837A patent/CA2537837A1/en not_active Abandoned
- 2004-09-13 US US10/940,884 patent/US7700652B2/en not_active Expired - Fee Related
- 2004-09-13 NZ NZ545884A patent/NZ545884A/en unknown
- 2004-09-13 EP EP04788728A patent/EP1670451A4/en not_active Withdrawn
-
2006
- 2006-03-20 IL IL174409A patent/IL174409A0/en unknown
- 2006-04-10 NO NO20061625A patent/NO20061625L/no not_active Application Discontinuation
-
2010
- 2010-03-09 US US12/720,414 patent/US20100166825A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007505149A5 (enExample) | ||
| US8101661B2 (en) | Polar hydrophilic prodrugs and non-standard amino acid conjugates of amphetamine and other stimulants and processes for making and using the same | |
| AU721190B2 (en) | Use of creatine analogues for the treatment of disorders of glucose metabolism | |
| JP2009538348A5 (enExample) | ||
| CN1283994A (zh) | 使用氨基硫醇化合物治疗神经和肾疾病和治疗毒性的方法 | |
| BRPI0807157A2 (pt) | Pró-farmacos hidrófilos polares de anfetamina e outros estimulantes e processos para fabricação e uso dos mesmos | |
| US11613528B2 (en) | Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use | |
| AU2023202321A1 (en) | Use of thyroid beta-agonists | |
| AU2017252126A1 (en) | Use of thyroid beta-agonists | |
| JP2025163212A (ja) | ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス | |
| RU2006112549A (ru) | Лечение или предупреждение синдрома беспокойных ног с использованием пролекарств аналогов гамк | |
| US20060094664A1 (en) | Deoxycholic acid derivatives for the treatment of acute dysfunctions of portal and hepatic venous circulation | |
| CN112912076A (zh) | 氨基甲酸酯化合物用于预防、缓解或治疗糖尿病性周围神经病变或化疗诱发性周围神经病变的用途 | |
| KR100379155B1 (ko) | 새로운 진통제 조성물 | |
| US6291441B1 (en) | Method of treating inflammatory bowel disorders | |
| BR122025010953A2 (pt) | Compostos de d-anfetamina, composição que compreende os mesmos, kit que compreende a dita composição e uso terapêutico dos ditos compostos | |
| HK40078104A (en) | D-amphetamine compounds, compositions, and processes for making and using the same | |
| HK40077785A (en) | D-amphetamine compounds, compositions, and processes for making and using the same | |
| HK40105778A (zh) | 包含酶可裂解的前药和萘莫司他的组合物及其使用方法 | |
| US20200338098A1 (en) | Conjoint Therapies with Inhibitors of Glucose Production | |
| WO2005056019A1 (ja) | 悪性黒色腫治療剤 | |
| JP2005534666A5 (enExample) | ||
| JP2003119144A (ja) | 胆汁酸誘導体を有効成分とする大腸癌予防／治療剤 | |
| EP1923054A1 (en) | Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator |